Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BENITEC BIOPHARMA INC.

(BNTC)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
2.56(c) 2.39(c) 2.57(c) 2.41(c) 2.49(c) Last
17 010 49 212 64 178 24 952 21 492 Volume
-4.79% -6.64% +7.53% -6.23% +3.32% Change
More quotes
Estimated financial data (e)
Sales 2020 0,10 M - -
Net income 2020 -8,27 M - -
Net cash position 2020 9,40 M - -
P/E ratio 2020 -1,41x
Yield 2020 -
Sales 2021 0,06 M - -
Net income 2021 -13,9 M - -
Net cash position 2021 19,6 M - -
P/E ratio 2021 -1,75x
Yield 2021 -
Capitalization 20,3 M 20,3 M -
EV / Sales 2020 -9,08x
EV / Sales 2021 234x
Nbr of Employees -
Free-Float 90,1%
More Financials
Company
Benitec Biopharma Inc is an Australia-based biotechnology company. The Company is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The Company's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in... 
More about the company
All news about BENITEC BIOPHARMA INC.
01/21BENITEC BIOPHARMA : Submission of Matters to a Vote of Security Holders - Form 8-K/A
PU
01/21BENITEC BIOPHARMA INC. Submission of Matters to a Vote of Security Holders (form 8-K/A..
AQ
2021BENITEC BIOPHARMA : Modification of Security Holder Rights - Form 8-K
PU
2021BENITEC BIOPHARMA INC. : Material Modification to Rights of Security Holders, Amendments t..
AQ
2021BENITEC BIOPHARMA INC. : Change in Directors or Principal Officers, Submission of Matters ..
AQ
2021INSIDER BUY : Benitec Biopharma
MT
2021BENITEC BIOPHARMA : Discloses Q1 2022 Financial Results - Form 8-K
PU
2021Benitec Biopharma Inc. Reports Earnings Results for the First Quarter Ended September 3..
CI
2021BENITEC BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and..
AQ
2021BENITEC BIOPHARMA : Provides Operational Update and Releases its 2021 Fiscal Year-End Fina..
PU
2021BENITEC BIOPHARMA : Annual Report (SEC Filing - 10-K)
PU
2021Benitec Biopharma Inc. Reports Earnings Results for the Full Year Ended June 30, 2021
CI
2021BENITEC BIOPHARMA : to present at H.C. Wainwright's 23rd Annual Global Investment Conferen..
PR
2021BENITEC BIOPHARMA : Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for ..
PR
2021Benitec Biopharma Inc. Provides Overview of the BB-301 Phase 1B/2A Clinical Trial Desig..
CI
More news
News in other languages on BENITEC BIOPHARMA INC.
2021ACHAT D'INITIÉS : Benitec Biopharma
2021MISE À JOUR : Benitec Biopharma s'effondre après avoir proposé une offre de rachat d'actio..
2021Benitec Biopharma porte à 12,9 millions de dollars le montant de son offre d'actions or..
2021MISE À JOUR SECTORIELLE : Les actions du secteur de la santé chutent suite à la retraite d..
2021MISE À JOUR SECTORIELLE : Les actions du secteur de la santé reculent en raison du poids d..
More news
Chart BENITEC BIOPHARMA INC.
Duration : Period :
Benitec Biopharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BENITEC BIOPHARMA INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Jerel A. Banks Chairman
Peter Roelvink Senior Director Research
Megan Boston Executive Director & Compliance Officer
J. Kevin Buchi Independent Non-Executive Director
Peter Francis Chairman
Sector and Competitors
1st jan.Capi. (M$)
BENITEC BIOPHARMA INC.-4.96%20
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508